Schedule 13G Filing for Tango Therapeutics, Inc.

The Schedule 13G filing reports the beneficial ownership of common stock in Tango Therapeutics, Inc. by several entities and individuals, collectively referred to as the Reporting Persons. As of September 19, 2025, Invus Public Equities, L.P. directly held 5,082,716 shares (4.6% of the total shares outstanding), and Avicenna Life Sci Master Fund LP directly held 800,472 shares (0.7% of the total shares outstanding). Raymond Debbane, through his control of various entities, may be deemed to beneficially own a total of 5,883,188 shares (5.3% of the total shares outstanding). The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, and the Reporting Persons certify that the shares were not acquired for the purpose of influencing the control of the issuer.